Komori
ReproCELL (4978) · TargetPresentation of the following fiscal year's earnings forecast

Sales growth and narrower losses for the fiscal year ending March 2021

First written in FY2020. . Latest entry: FY2021.

4entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2020 – FY20212020: 220202021: 22021
Same theme, other companies

The whole theme swung hardest in 2021: 2 of 20 companies on the "Worse" side.

10 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 21 companies compared. The sentences above are computed from all 21.
Full recordFilings, disclosures and news, newest first
  1. FY2021Presentation of the following fiscal year's earnings forecastAnnual report

    「For the fiscal year ending March 2022, the company forecasts net sales of ¥2,106 million, up 63.8% from the current fiscal year, an operating loss of ¥377 million, compared with a loss of ¥1,048 million in the current fiscal year, an ordinary loss of ¥157 million, compared with a loss of ¥788 million, and a net loss attributable to owners of the parent of ¥157 million, compared with a loss of ¥812 million.」

    Following the full-year results for FY2021, the company has presented a forecast for the fiscal year ending March 2022 of higher sales and narrower operating, ordinary and net losses.
  2. FY2021-Q3Presentation of third-quarter resultsAnnual report

    「As a result, for the nine months ended the third quarter, revenue was ¥949 million, up 6.5% year on year, operating loss was ¥764 million, compared with a loss of ¥671 million in the same period of the previous year, ordinary loss was ¥657 million, compared with a loss of ¥656 million, and quarterly net loss attributable to owners of the parent was ¥658 million, compared with a loss of ¥663 million.」

    The company has presented cumulative results for the first 3 quarters of the fiscal year ending March 2021. Net sales were up 6.5% year on year and the operating loss widened, but the company's own assessment of progress toward its full-year target is not stated.
  3. FY2021-Q1Presentation of first-quarter resultsAnnual report

    「As a result, for the first quarter of the fiscal year, revenue was ¥168 million, down 34.5% year on year, operating loss was ¥289 million, compared with a loss of ¥225 million in the same period of the previous year, ordinary loss was ¥207 million, compared with a loss of ¥229 million, and quarterly net loss attributable to owners of the parent was ¥208 million, compared with a loss of ¥229 million.」

    The company has presented results for the first quarter of the fiscal year ending March 2021. Net sales were below the year-earlier period and the operating loss widened, but the company's own assessment of progress toward its full-year target is not stated.
  4. FY2020First statedAnnual report

    「For the fiscal year ending March 2021, the company forecasts net sales of ¥1,295 million, up 8.0% from the current fiscal year, an operating loss of ¥1,044 million, compared with a loss of ¥908 million in the current fiscal year, an ordinary loss of ¥893 million, compared with a loss of ¥891 million, and a net loss attributable to owners of the parent of ¥893 million, compared with a loss of ¥1,016 million.」

    For the fiscal year ending March 2021, the company quantitatively forecasts higher net sales and narrower operating, ordinary and net losses.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Sales growth and narrower losses for the fiscal year ending March 2021 | ReproCELL Incorporated (4978) | Komori